Case Letter

To the Editor:

Daptomycin is an antibiotic that is increasingly being prescribed for the treatment of gram-positive infections in conditions such as endocarditis, bacteremia, and soft tissue infections. Dermatologic adverse effects associated with daptomycin are not uncommon. Approximately 6.7% of patients taking daptomycin have been reported to develop a rash, and 5.8% have developed pruritus.¹ As the popularity of daptomycin increases for the treatment of drug-resistant Staphylococcus aureus and Enterococcus infections, it is important for physicians to be aware of the potential dermatologic complications that may be associated with the use of this novel antibiotic in clinical practice.

A 56-year-old woman was admitted to our hospital with a fever (temperature, 38.7°C), hypotension (blood pressure, 94/54), and a new truncal rash. The patient had undergone knee replacement surgery 5 weeks prior. She developed an infection 2 weeks following surgery and was started on vancomycin, levofloxacin, and rifampin. She continued on this regimen for 3 weeks. Four days prior to presentation the patient developed erythema and edema of the face consistent with red man syndrome; levofloxacin was discontinued and vancomycin and rifampin were replaced with daptomycin (500 mg/10 mL). When the patient was admitted to our hospital 4 days later, vasopressor support was initiated for presumed septic shock due to infection from a peripherally inserted central catheter line. The white blood cell count as well as absolute neutrophil and eosinophil levels were within reference range, but liver function tests were elevated (aspartate aminotransferase, 353 U/L [reference range, <40 U/L]; alanine aminotransferase, 386 U/L [reference range, <40 U/L]). Physical examination revealed confluent erythematous macules with scattered pinpoint pustules on the neck, trunk, arms, and legs (Figure 1). There was facial edema but no lymphadenopathy was noted.

Figure 1. Erythematous macules and patches with scattered pinpoint pustules on the right upper arm and shoulder.

Histologic examination revealed intraepidermal neutrophils with focal aggregation into subcorneal pustules. Papillary dermal edema was prominent with a superficial perivascular and interstitial inflammatory infiltrate of lymphocytes, neutrophils, and numerous eosinophils (Figure 2). These findings were consistent with acute generalized exanthematous pustulosis (AGEP). All blood cultures were negative. Within a few days the edema and erythema subsided, leaving desquamating erythematous patches. The patient’s other medications included simvastatin, citalopram, levothyroxine, hydrocortisone cream, celecoxib, and pramipexole, all of which she had been taking for at least 3 years. She also was taking oxycodone hydrochloride and warfarin, which were initiated after the knee replacement. Based on the patient’s history as well as the clinical and histologic appearance, she was diagnosed with daptomycin-induced AGEP.

Acute generalized exanthematous pustulosis is a less common acute febrile drug eruption consisting of small, primarily nonfollicular sterile pustules arising within large areas of edematous erythema, often beginning on the face or intertriginous zones and then disseminating. There may be associated burning or pruritus. Edema of the face and hands is not uncommon and mucous membranes may be involved. The time from drug administration to skin eruption is relatively short, usually less than 2 days. The lesions generally last 1 to 2 weeks after onset and spontaneously resolve with superficial desquamation.

Although AGEP most commonly is triggered by β-lactam and macrolide antibiotics, AGEP also has been associated with chromium supplements,² seasonings containing urushiol, and parasitic or viral infections.³ A multinational case-control study by Sidoroff et al⁴ showed no increased family or personal history of psoriasis in patients with AGEP; our patient also did not have a history of psoriasis.

Daptomycin is a semisynthetic lipopeptide antibiotic derived from the fermentation of Streptomyces roseosporus that exerts its bactericidal action by disrupting plasma membrane function and inducing cell depolarization. Daptomycin is active against many gram-positive bacteria including vancomycin-resistant Enterococcus faecalis and methicillin-resistant S aureus.^5,6 It currently is approved for the treatment of complicated skin and skin structure infections due to gram-positive cocci and bacterial endocarditis.

In animal studies, the most common adverse effects of treatment with daptomycin were myopathy and elevated serum creatine kinase levels, which were reversible on discontinuation of the drug.⁵ Thus weekly measurements of creatine kinase levels are recommended while receiving daptomycin therapy, especially if the patient also is taking a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Other common adverse effects in human trials include eosinophilic pneumonia and diarrhea associated with Clostridium difficile infection.¹

Figure 2. Spongiform pustules within the superficial epidermal layers, prominent edema of the papillary dermis, and a mixed perivascular infiltrate of predominantly neutrophils as well as eosinophils (H&amp;E, original magnification ×20).

In phase 3 human trials, dermatologic adverse effects associated with daptomycin were not uncommon, affecting up to 30% of patients in some trials. Side effects included rash (4.3%–6.7%), generalized erythema (5%), pruritus (2.8%–5.8%), heat rash (<1%), and eczema (<1%).¹ In postmarketing data collection worldwide, a vesiculobullous rash with or without mucous membrane involvement was reported in an unknown percentage of patients.

Our case of a pustular eruption associated with the use of daptomycin is unique. In our patient, the clinical and histologic presentation was consistent with the diagnosis of AGEP. Based on the patient’s history of starting daptomycin 4 days prior to the onset of symptoms, we believe that the drug was associated with the development of AGEP. She had not recently undergone any other medication changes, as she had been taking her other medications for at least 3 years with the exception of warfarin and oxycodone hydrochloride, which were initiated 5 weeks prior to the eruption.

Because of its unique mechanism of action as well as the prevalent phenomenon of antibiotic resistance, daptomycin is increasingly used for the treatment of complicated skin and skin structure infections caused by gram-positive organisms. As the use of daptomycin increases, it is important for physicians to be aware of its potential cutaneous complications.

To the Editor:

Daptomycin is an antibiotic that is increasingly being prescribed for the treatment of gram-positive infections in conditions such as endocarditis, bacteremia, and soft tissue infections. Dermatologic adverse effects associated with daptomycin are not uncommon. Approximately 6.7% of patients taking daptomycin have been reported to develop a rash, and 5.8% have developed pruritus.¹ As the popularity of daptomycin increases for the treatment of drug-resistant Staphylococcus aureus and Enterococcus infections, it is important for physicians to be aware of the potential dermatologic complications that may be associated with the use of this novel antibiotic in clinical practice.

A 56-year-old woman was admitted to our hospital with a fever (temperature, 38.7°C), hypotension (blood pressure, 94/54), and a new truncal rash. The patient had undergone knee replacement surgery 5 weeks prior. She developed an infection 2 weeks following surgery and was started on vancomycin, levofloxacin, and rifampin. She continued on this regimen for 3 weeks. Four days prior to presentation the patient developed erythema and edema of the face consistent with red man syndrome; levofloxacin was discontinued and vancomycin and rifampin were replaced with daptomycin (500 mg/10 mL). When the patient was admitted to our hospital 4 days later, vasopressor support was initiated for presumed septic shock due to infection from a peripherally inserted central catheter line. The white blood cell count as well as absolute neutrophil and eosinophil levels were within reference range, but liver function tests were elevated (aspartate aminotransferase, 353 U/L [reference range, <40 U/L]; alanine aminotransferase, 386 U/L [reference range, <40 U/L]). Physical examination revealed confluent erythematous macules with scattered pinpoint pustules on the neck, trunk, arms, and legs (Figure 1). There was facial edema but no lymphadenopathy was noted.

Figure 1. Erythematous macules and patches with scattered pinpoint pustules on the right upper arm and shoulder.

Histologic examination revealed intraepidermal neutrophils with focal aggregation into subcorneal pustules. Papillary dermal edema was prominent with a superficial perivascular and interstitial inflammatory infiltrate of lymphocytes, neutrophils, and numerous eosinophils (Figure 2). These findings were consistent with acute generalized exanthematous pustulosis (AGEP). All blood cultures were negative. Within a few days the edema and erythema subsided, leaving desquamating erythematous patches. The patient’s other medications included simvastatin, citalopram, levothyroxine, hydrocortisone cream, celecoxib, and pramipexole, all of which she had been taking for at least 3 years. She also was taking oxycodone hydrochloride and warfarin, which were initiated after the knee replacement. Based on the patient’s history as well as the clinical and histologic appearance, she was diagnosed with daptomycin-induced AGEP.

Acute generalized exanthematous pustulosis is a less common acute febrile drug eruption consisting of small, primarily nonfollicular sterile pustules arising within large areas of edematous erythema, often beginning on the face or intertriginous zones and then disseminating. There may be associated burning or pruritus. Edema of the face and hands is not uncommon and mucous membranes may be involved. The time from drug administration to skin eruption is relatively short, usually less than 2 days. The lesions generally last 1 to 2 weeks after onset and spontaneously resolve with superficial desquamation.

Although AGEP most commonly is triggered by β-lactam and macrolide antibiotics, AGEP also has been associated with chromium supplements,² seasonings containing urushiol, and parasitic or viral infections.³ A multinational case-control study by Sidoroff et al⁴ showed no increased family or personal history of psoriasis in patients with AGEP; our patient also did not have a history of psoriasis.

Daptomycin is a semisynthetic lipopeptide antibiotic derived from the fermentation of Streptomyces roseosporus that exerts its bactericidal action by disrupting plasma membrane function and inducing cell depolarization. Daptomycin is active against many gram-positive bacteria including vancomycin-resistant Enterococcus faecalis and methicillin-resistant S aureus.^5,6 It currently is approved for the treatment of complicated skin and skin structure infections due to gram-positive cocci and bacterial endocarditis.

In animal studies, the most common adverse effects of treatment with daptomycin were myopathy and elevated serum creatine kinase levels, which were reversible on discontinuation of the drug.⁵ Thus weekly measurements of creatine kinase levels are recommended while receiving daptomycin therapy, especially if the patient also is taking a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Other common adverse effects in human trials include eosinophilic pneumonia and diarrhea associated with Clostridium difficile infection.¹

Figure 2. Spongiform pustules within the superficial epidermal layers, prominent edema of the papillary dermis, and a mixed perivascular infiltrate of predominantly neutrophils as well as eosinophils (H&amp;E, original magnification ×20).

In phase 3 human trials, dermatologic adverse effects associated with daptomycin were not uncommon, affecting up to 30% of patients in some trials. Side effects included rash (4.3%–6.7%), generalized erythema (5%), pruritus (2.8%–5.8%), heat rash (<1%), and eczema (<1%).¹ In postmarketing data collection worldwide, a vesiculobullous rash with or without mucous membrane involvement was reported in an unknown percentage of patients.

Our case of a pustular eruption associated with the use of daptomycin is unique. In our patient, the clinical and histologic presentation was consistent with the diagnosis of AGEP. Based on the patient’s history of starting daptomycin 4 days prior to the onset of symptoms, we believe that the drug was associated with the development of AGEP. She had not recently undergone any other medication changes, as she had been taking her other medications for at least 3 years with the exception of warfarin and oxycodone hydrochloride, which were initiated 5 weeks prior to the eruption.

Because of its unique mechanism of action as well as the prevalent phenomenon of antibiotic resistance, daptomycin is increasingly used for the treatment of complicated skin and skin structure infections caused by gram-positive organisms. As the use of daptomycin increases, it is important for physicians to be aware of its potential cutaneous complications.

To the Editor:

Daptomycin is an antibiotic that is increasingly being prescribed for the treatment of gram-positive infections in conditions such as endocarditis, bacteremia, and soft tissue infections. Dermatologic adverse effects associated with daptomycin are not uncommon. Approximately 6.7% of patients taking daptomycin have been reported to develop a rash, and 5.8% have developed pruritus.¹ As the popularity of daptomycin increases for the treatment of drug-resistant Staphylococcus aureus and Enterococcus infections, it is important for physicians to be aware of the potential dermatologic complications that may be associated with the use of this novel antibiotic in clinical practice.

A 56-year-old woman was admitted to our hospital with a fever (temperature, 38.7°C), hypotension (blood pressure, 94/54), and a new truncal rash. The patient had undergone knee replacement surgery 5 weeks prior. She developed an infection 2 weeks following surgery and was started on vancomycin, levofloxacin, and rifampin. She continued on this regimen for 3 weeks. Four days prior to presentation the patient developed erythema and edema of the face consistent with red man syndrome; levofloxacin was discontinued and vancomycin and rifampin were replaced with daptomycin (500 mg/10 mL). When the patient was admitted to our hospital 4 days later, vasopressor support was initiated for presumed septic shock due to infection from a peripherally inserted central catheter line. The white blood cell count as well as absolute neutrophil and eosinophil levels were within reference range, but liver function tests were elevated (aspartate aminotransferase, 353 U/L [reference range, <40 U/L]; alanine aminotransferase, 386 U/L [reference range, <40 U/L]). Physical examination revealed confluent erythematous macules with scattered pinpoint pustules on the neck, trunk, arms, and legs (Figure 1). There was facial edema but no lymphadenopathy was noted.

Figure 1. Erythematous macules and patches with scattered pinpoint pustules on the right upper arm and shoulder.

Histologic examination revealed intraepidermal neutrophils with focal aggregation into subcorneal pustules. Papillary dermal edema was prominent with a superficial perivascular and interstitial inflammatory infiltrate of lymphocytes, neutrophils, and numerous eosinophils (Figure 2). These findings were consistent with acute generalized exanthematous pustulosis (AGEP). All blood cultures were negative. Within a few days the edema and erythema subsided, leaving desquamating erythematous patches. The patient’s other medications included simvastatin, citalopram, levothyroxine, hydrocortisone cream, celecoxib, and pramipexole, all of which she had been taking for at least 3 years. She also was taking oxycodone hydrochloride and warfarin, which were initiated after the knee replacement. Based on the patient’s history as well as the clinical and histologic appearance, she was diagnosed with daptomycin-induced AGEP.

Acute generalized exanthematous pustulosis is a less common acute febrile drug eruption consisting of small, primarily nonfollicular sterile pustules arising within large areas of edematous erythema, often beginning on the face or intertriginous zones and then disseminating. There may be associated burning or pruritus. Edema of the face and hands is not uncommon and mucous membranes may be involved. The time from drug administration to skin eruption is relatively short, usually less than 2 days. The lesions generally last 1 to 2 weeks after onset and spontaneously resolve with superficial desquamation.

Although AGEP most commonly is triggered by β-lactam and macrolide antibiotics, AGEP also has been associated with chromium supplements,² seasonings containing urushiol, and parasitic or viral infections.³ A multinational case-control study by Sidoroff et al⁴ showed no increased family or personal history of psoriasis in patients with AGEP; our patient also did not have a history of psoriasis.

Daptomycin is a semisynthetic lipopeptide antibiotic derived from the fermentation of Streptomyces roseosporus that exerts its bactericidal action by disrupting plasma membrane function and inducing cell depolarization. Daptomycin is active against many gram-positive bacteria including vancomycin-resistant Enterococcus faecalis and methicillin-resistant S aureus.^5,6 It currently is approved for the treatment of complicated skin and skin structure infections due to gram-positive cocci and bacterial endocarditis.

In animal studies, the most common adverse effects of treatment with daptomycin were myopathy and elevated serum creatine kinase levels, which were reversible on discontinuation of the drug.⁵ Thus weekly measurements of creatine kinase levels are recommended while receiving daptomycin therapy, especially if the patient also is taking a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Other common adverse effects in human trials include eosinophilic pneumonia and diarrhea associated with Clostridium difficile infection.¹

Figure 2. Spongiform pustules within the superficial epidermal layers, prominent edema of the papillary dermis, and a mixed perivascular infiltrate of predominantly neutrophils as well as eosinophils (H&amp;E, original magnification ×20).

In phase 3 human trials, dermatologic adverse effects associated with daptomycin were not uncommon, affecting up to 30% of patients in some trials. Side effects included rash (4.3%–6.7%), generalized erythema (5%), pruritus (2.8%–5.8%), heat rash (<1%), and eczema (<1%).¹ In postmarketing data collection worldwide, a vesiculobullous rash with or without mucous membrane involvement was reported in an unknown percentage of patients.

Our case of a pustular eruption associated with the use of daptomycin is unique. In our patient, the clinical and histologic presentation was consistent with the diagnosis of AGEP. Based on the patient’s history of starting daptomycin 4 days prior to the onset of symptoms, we believe that the drug was associated with the development of AGEP. She had not recently undergone any other medication changes, as she had been taking her other medications for at least 3 years with the exception of warfarin and oxycodone hydrochloride, which were initiated 5 weeks prior to the eruption.

Because of its unique mechanism of action as well as the prevalent phenomenon of antibiotic resistance, daptomycin is increasingly used for the treatment of complicated skin and skin structure infections caused by gram-positive organisms. As the use of daptomycin increases, it is important for physicians to be aware of its potential cutaneous complications.

To the Editor:

Samarin et al¹ reported a case of superficial cervical ulceration that was proposed to be unilateral ulcerations restricted to a dermatome, representing a new clinical variant in the spectrum of trigeminal trophic syndrome (TTS) termed cervical trophic syndrome. The patient was a cognitively impaired elderly woman with a superficial ulceration on the posterior aspect of the neck and a history of herpes zoster (HZ) infection of the affected dermatome.¹ We report a similar case of a patient with underlying spinal pathology and discuss these cases as a spectrum between TTS and notalgia paresthetica whereby lesions of peripheral spinal nerves may lead to unilateral ulcerations restricted to a dermatome.

A 66-year-old man with a history of mental retardation and end-stage renal disease presented with an ulceration on the posterior aspect of the neck of approximately 9 months’ duration. Cervical and thoracic radiographs showed levoscoliosis and moderate degenerative disc disease as well as facet arthropathy in the cervical spine. His history was negative for HZ infection. The patient admitted to a chronic inability to control scratching of the area. On examination a 15×15-cm, unilateral, shallow ulceration was seen, with sharp midline demarcation involving the C3-C5 dermatomes (Figure 1). He underwent debridement with general anesthesia, daily dressing changes, and a renal dose of gabapentin 100 mg twice daily. During treatment, 2 biopsies were unremarkable and only showed ulceration and fibrosis. He continued to make progress over the next 2 months with successive in-office debridement and wound care therapy (Figure 2). Unfortunately, he died of an unrelated cause during follow-up.

Figure 2. After 2 months of gabapentin and wound care therapy, the patient’s ulceration began to heal.

Figure 1. Unilateral, well-demarcated, shallow ulceration (15×15 cm) involving the C3-C5 dermatomes (A and B ) .

Our patient’s history and presentation are best explained as a variant of notalgia paresthetica complicated by self-mutilation. Notalgia paresthetica typically presents as unilateral pruritus over the scapular border of the upper back. The classic distribution of pruritus of the T2-T6 dermatomes is strongly associated with degenerative spinal changes; however, degeneration solely confined to cervical segments has been described in etiologic investigations of notalgia paresthetica.^2,3 Our case and the case reported by Samarin et al¹ involved the C3-C5 dermatomes. Although cases of pruritus confined to the neck also have been previously classified as brachioradial pruritus, the cases described by Wallengren and Sundler⁴ were proposed to have predisposing spinal disease as well as a component of solar-induced nerve injury. Because cervical ulceration restricted to a dermatome was present in the case described by Samarin et al,¹ it appeared to be associated with antecedent HZ infection and was suggested to represent a new clinical syndrome or variant of TTS. Although classically due to mechanical ablation of the trigeminal ganglion, TTS also may be secondary to vascular or viral insult to the trigeminal ganglion or nerve.^5,6 The etiology typically is presumed to be secondary to self-mutilation due to underlying paresthesia or dysesthesia. The trigeminal ganglion only is unique in size and location when compared to spinal dorsal root ganglia.

These 2 cases suggest that any insult to any sensory nerve, whether compression related, viral, or vascular, can produce trophic ulcerations secondary to pruritus or self-mutilation. It is likely that TTS is more commonly encountered than other spinal trophic lesions due to the size and location of the trigeminal nerve and ganglion.

Ulceration is not a typical feature of notalgia paresthetica or brachioradial pruritus; a history of self-mutilation due to underlying paresthesia is consistent with the diagnosis. These 2 cases represent notalgia paresthetica and postherpetic pruritus in patients with extreme self-mutilative responses to previously described neuropathic itch syndromes. Spinal trophic syndromes likely are a spectrum of disorders in continuum with TTS.

To the Editor:

Samarin et al¹ reported a case of superficial cervical ulceration that was proposed to be unilateral ulcerations restricted to a dermatome, representing a new clinical variant in the spectrum of trigeminal trophic syndrome (TTS) termed cervical trophic syndrome. The patient was a cognitively impaired elderly woman with a superficial ulceration on the posterior aspect of the neck and a history of herpes zoster (HZ) infection of the affected dermatome.¹ We report a similar case of a patient with underlying spinal pathology and discuss these cases as a spectrum between TTS and notalgia paresthetica whereby lesions of peripheral spinal nerves may lead to unilateral ulcerations restricted to a dermatome.

A 66-year-old man with a history of mental retardation and end-stage renal disease presented with an ulceration on the posterior aspect of the neck of approximately 9 months’ duration. Cervical and thoracic radiographs showed levoscoliosis and moderate degenerative disc disease as well as facet arthropathy in the cervical spine. His history was negative for HZ infection. The patient admitted to a chronic inability to control scratching of the area. On examination a 15×15-cm, unilateral, shallow ulceration was seen, with sharp midline demarcation involving the C3-C5 dermatomes (Figure 1). He underwent debridement with general anesthesia, daily dressing changes, and a renal dose of gabapentin 100 mg twice daily. During treatment, 2 biopsies were unremarkable and only showed ulceration and fibrosis. He continued to make progress over the next 2 months with successive in-office debridement and wound care therapy (Figure 2). Unfortunately, he died of an unrelated cause during follow-up.

Figure 2. After 2 months of gabapentin and wound care therapy, the patient’s ulceration began to heal.

Figure 1. Unilateral, well-demarcated, shallow ulceration (15×15 cm) involving the C3-C5 dermatomes (A and B ) .

Our patient’s history and presentation are best explained as a variant of notalgia paresthetica complicated by self-mutilation. Notalgia paresthetica typically presents as unilateral pruritus over the scapular border of the upper back. The classic distribution of pruritus of the T2-T6 dermatomes is strongly associated with degenerative spinal changes; however, degeneration solely confined to cervical segments has been described in etiologic investigations of notalgia paresthetica.^2,3 Our case and the case reported by Samarin et al¹ involved the C3-C5 dermatomes. Although cases of pruritus confined to the neck also have been previously classified as brachioradial pruritus, the cases described by Wallengren and Sundler⁴ were proposed to have predisposing spinal disease as well as a component of solar-induced nerve injury. Because cervical ulceration restricted to a dermatome was present in the case described by Samarin et al,¹ it appeared to be associated with antecedent HZ infection and was suggested to represent a new clinical syndrome or variant of TTS. Although classically due to mechanical ablation of the trigeminal ganglion, TTS also may be secondary to vascular or viral insult to the trigeminal ganglion or nerve.^5,6 The etiology typically is presumed to be secondary to self-mutilation due to underlying paresthesia or dysesthesia. The trigeminal ganglion only is unique in size and location when compared to spinal dorsal root ganglia.

These 2 cases suggest that any insult to any sensory nerve, whether compression related, viral, or vascular, can produce trophic ulcerations secondary to pruritus or self-mutilation. It is likely that TTS is more commonly encountered than other spinal trophic lesions due to the size and location of the trigeminal nerve and ganglion.

Ulceration is not a typical feature of notalgia paresthetica or brachioradial pruritus; a history of self-mutilation due to underlying paresthesia is consistent with the diagnosis. These 2 cases represent notalgia paresthetica and postherpetic pruritus in patients with extreme self-mutilative responses to previously described neuropathic itch syndromes. Spinal trophic syndromes likely are a spectrum of disorders in continuum with TTS.

To the Editor:

Samarin et al¹ reported a case of superficial cervical ulceration that was proposed to be unilateral ulcerations restricted to a dermatome, representing a new clinical variant in the spectrum of trigeminal trophic syndrome (TTS) termed cervical trophic syndrome. The patient was a cognitively impaired elderly woman with a superficial ulceration on the posterior aspect of the neck and a history of herpes zoster (HZ) infection of the affected dermatome.¹ We report a similar case of a patient with underlying spinal pathology and discuss these cases as a spectrum between TTS and notalgia paresthetica whereby lesions of peripheral spinal nerves may lead to unilateral ulcerations restricted to a dermatome.

A 66-year-old man with a history of mental retardation and end-stage renal disease presented with an ulceration on the posterior aspect of the neck of approximately 9 months’ duration. Cervical and thoracic radiographs showed levoscoliosis and moderate degenerative disc disease as well as facet arthropathy in the cervical spine. His history was negative for HZ infection. The patient admitted to a chronic inability to control scratching of the area. On examination a 15×15-cm, unilateral, shallow ulceration was seen, with sharp midline demarcation involving the C3-C5 dermatomes (Figure 1). He underwent debridement with general anesthesia, daily dressing changes, and a renal dose of gabapentin 100 mg twice daily. During treatment, 2 biopsies were unremarkable and only showed ulceration and fibrosis. He continued to make progress over the next 2 months with successive in-office debridement and wound care therapy (Figure 2). Unfortunately, he died of an unrelated cause during follow-up.

Figure 2. After 2 months of gabapentin and wound care therapy, the patient’s ulceration began to heal.

Figure 1. Unilateral, well-demarcated, shallow ulceration (15×15 cm) involving the C3-C5 dermatomes (A and B ) .

Our patient’s history and presentation are best explained as a variant of notalgia paresthetica complicated by self-mutilation. Notalgia paresthetica typically presents as unilateral pruritus over the scapular border of the upper back. The classic distribution of pruritus of the T2-T6 dermatomes is strongly associated with degenerative spinal changes; however, degeneration solely confined to cervical segments has been described in etiologic investigations of notalgia paresthetica.^2,3 Our case and the case reported by Samarin et al¹ involved the C3-C5 dermatomes. Although cases of pruritus confined to the neck also have been previously classified as brachioradial pruritus, the cases described by Wallengren and Sundler⁴ were proposed to have predisposing spinal disease as well as a component of solar-induced nerve injury. Because cervical ulceration restricted to a dermatome was present in the case described by Samarin et al,¹ it appeared to be associated with antecedent HZ infection and was suggested to represent a new clinical syndrome or variant of TTS. Although classically due to mechanical ablation of the trigeminal ganglion, TTS also may be secondary to vascular or viral insult to the trigeminal ganglion or nerve.^5,6 The etiology typically is presumed to be secondary to self-mutilation due to underlying paresthesia or dysesthesia. The trigeminal ganglion only is unique in size and location when compared to spinal dorsal root ganglia.

These 2 cases suggest that any insult to any sensory nerve, whether compression related, viral, or vascular, can produce trophic ulcerations secondary to pruritus or self-mutilation. It is likely that TTS is more commonly encountered than other spinal trophic lesions due to the size and location of the trigeminal nerve and ganglion.

Ulceration is not a typical feature of notalgia paresthetica or brachioradial pruritus; a history of self-mutilation due to underlying paresthesia is consistent with the diagnosis. These 2 cases represent notalgia paresthetica and postherpetic pruritus in patients with extreme self-mutilative responses to previously described neuropathic itch syndromes. Spinal trophic syndromes likely are a spectrum of disorders in continuum with TTS.

To the Editor:

Acrokeratosis paraneoplastica (AP) of Bazex is a rare but distinctive acral psoriasiform dermatosis associated with internal malignancy, usually squamous cell carcinoma (SCC), of the upper aerodigestive tract.^1,2 Recognizing this paraneoplastic condition is paramount because cutaneous findings often precede the onset of symptoms associated with an occult malignancy.³

A 76-year-old woman with adenocarcinoma of the transverse colon of 3 years’ duration was referred to the dermatology department. She had a hemicolectomy and was doing well until tumor recurrence with peritoneal metastasis was detected following an exploratory laparotomy 1 year prior to presentation to us. She underwent a total hysterectomy and bilateral salpingo-oophorectomy. Palliative chemotherapy was initiated, and she completed 5 cycles of capecitabine and oxaliplatin. Long-term medications for diabetes mellitus, hypertension, and hyperlipidemia included glibenclamide, nifedipine, hydrochlorothiazide, and losartan. The patient had a progressive pruritic rash of 6 months’ duration that started on the hands and forearms and spread to involve the feet and lower limbs as well as the ears and face. She also experienced progressive thickening of the palms and soles. She had been treated with topical steroids and emollients with no improvement. Clinical examination revealed erythematous scaly patches on all of her limbs, especially on the elbows and knees, and on the ear helices and nose. There also was notable palmoplantar keratoderma with central sparing (Figure 1), onycholysis, and subungual hyperkeratosis. A skin biopsy of the forearm was performed, and histology revealed orthokeratosis, hypergranulosis and basal vacuolar alteration, and superficial perivascular lymphohistiocytic infiltrate with melanophages (Figure 2). Direct immunofluorescence studies and fungal cultures were negative. The cutaneous features of a treatment-resistant acral dermatosis supported the clinical diagnosis of AP, especially in the setting of an internal malignancy. The patient was started on palliative radiotherapy with no notable resolution of the cutaneous lesions. She was lost to follow-up.

Figure 1. Palmoplantar keratoderma with central sparing of the palms and soles, onycholysis, and subungual hyperkeratosis .

First described by Bazex et al¹ in 1965, AP is an uncommon but well-recognized paraneoplastic dermatosis associated with an underlying neoplasm. Fewer than 160 cases have been reported, and the majority of cases have been men older than 40 years. The most commonly associated malignancy was SCC (at least 50% of reported cases) involving mainly the oropharynx and larynx, with lung and esophageal SCC also described.^2-4 Only a few cases of adenocarcinoma-associated AP have been described, such as adenocarcinoma of the lung, prostate, and stomach.^3-5 In a reported case of AP associated with early colon adenocarcinoma, the patient had remarkable cutaneous resolution following successful tumor resection.⁶ Other reported rare hematologic associations included Hodgkin disease, peripheral T-cell lymphoma, and multiple myeloma.^3-5 Karabulut et al⁴ described a case associated with cholangiocarcinoma and studied the primary sites of malignancies in another 133 patients with AP (118 patients with documented cell type): oropharynx and larynx in 55 (41%); lung in 23 (17%); unknown location in 20 (15%); esophagus in 14 (11%); prostate in 3 (2%); stomach in 3 (2%); and isolated cases involving the liver, thymus, uterus, vulva, breast, urinary bladder, lymph nodes, and bone marrow.

Figure 2. Histologic examination revealed basal vacuolar alteration, hyperkeratosis, and superficial perivascular lymphohistiocytic infiltrate with melanophages (H&amp;E, original magnification ×40).

A review of 113 cases of AP showed that only 15% developed cutaneous lesions after the malignancy had been discovered; in the majority of cases (67%), cutaneous lesions were present for an average of 1 year preceding the diagnosis of malignancy.³ In our patient, the late-onset cutaneous involvement corresponded to the progression of the underlying colon adenocarcinoma. In the absence of initial cutaneous involvement or when successful treatment of a tumor results in cutaneous resolution, subsequent emergence of cutaneous lesions of AP signifies tumor progression. The evolution of cutaneous features in AP was well described by Bazex et al.¹ Stage 1 of the disease shows initial erythema and psoriasiform scaling of the fingers and toes, spreading to the nose and ear helices (hence acrokeratosis); the tumor frequently remains asymptomatic or undetected. Stage 2 shows palmoplantar keratoderma with central sparing and more extensive facial lesions; progression to stage 3 occurs if the tumor remains undetected or untreated, with further spread of psoriasiform lesions to the elbows, knees, trunk, and scalp.¹ Nail involvement occurs in nearly 75% of cases⁵; typical changes include subungual hyperkeratosis, onycholysis, longitudinal streaks, yellow pigmentation, and rarely onychomadesis. A high index of suspicion of AP is paramount when evaluating any recalcitrant acral dermatosis that fails to respond to appropriate therapy, especially in the presence of constitutional symptoms, typical bulbous enlargement of distal phalanges, or isolated involvement of helices. These findings should prompt physicians to perform an extensive search for an underlying malignancy with complete physical examination, particularly of the head and neck region, with appropriate endoscopic assessment and imaging studies.

A myriad of nonspecific histologic features of AP commonly reported include hyperkeratosis, parakeratosis, acanthosis, and dermal perivascular lymphohistiocytic infiltrate.⁷ Less common features include dyskeratotic keratinocytes, vacuolar degeneration, bandlike infiltrate, and melanin incontinence.⁷ The pathogenesis of AP remains elusive. A postulated immunologic mechanism is based on reports of immunoglobulins (IgG, IgA, IgM) and complement (C3) deposition along the basement membrane zone.⁸ Association with autoimmune disorders such as alopecia areata and vitiligo also has been reported.⁹ Another possible mechanism is cross-reactivity between antigens found in the tumor and skin, resulting in a T-cell–mediated immune response to tumorlike antigens in the epidermis, or secretion of tumor-originating growth factors responsible for the hyperkeratotic skin changes, such as epidermal growth factor, transforming growth factor a, or insulinlike growth factor 1.^3,7,10,11

Spontaneous remission of cutaneous lesions in untreated underlying malignancy is rare. Isolated reports of treatment using topical and systemic steroids, salicylic acid, topical vitamin D analogues, etretinate, and psoralen plus UVA showed minimal improvement.^5,7 The mainstay in attaining cutaneous resolution is to detect and eradicate the underlying neoplasm with surgery, chemotherapy, or radiotherapy, or combination therapy.

Our case is noteworthy because of the patient’s gender (female), underlying malignancy (adenocarcinoma of the colon), and late onset of cutaneous involvement, which are all uncommon associations related to paraneoplastic syndrome. The clinical features of AP should be recognized early to facilitate an extensive search for an occult malignancy, and late-onset cutaneous involvement also should be recognized as a marker of tumor relapse or progression.

To the Editor:

Acrokeratosis paraneoplastica (AP) of Bazex is a rare but distinctive acral psoriasiform dermatosis associated with internal malignancy, usually squamous cell carcinoma (SCC), of the upper aerodigestive tract.^1,2 Recognizing this paraneoplastic condition is paramount because cutaneous findings often precede the onset of symptoms associated with an occult malignancy.³

A 76-year-old woman with adenocarcinoma of the transverse colon of 3 years’ duration was referred to the dermatology department. She had a hemicolectomy and was doing well until tumor recurrence with peritoneal metastasis was detected following an exploratory laparotomy 1 year prior to presentation to us. She underwent a total hysterectomy and bilateral salpingo-oophorectomy. Palliative chemotherapy was initiated, and she completed 5 cycles of capecitabine and oxaliplatin. Long-term medications for diabetes mellitus, hypertension, and hyperlipidemia included glibenclamide, nifedipine, hydrochlorothiazide, and losartan. The patient had a progressive pruritic rash of 6 months’ duration that started on the hands and forearms and spread to involve the feet and lower limbs as well as the ears and face. She also experienced progressive thickening of the palms and soles. She had been treated with topical steroids and emollients with no improvement. Clinical examination revealed erythematous scaly patches on all of her limbs, especially on the elbows and knees, and on the ear helices and nose. There also was notable palmoplantar keratoderma with central sparing (Figure 1), onycholysis, and subungual hyperkeratosis. A skin biopsy of the forearm was performed, and histology revealed orthokeratosis, hypergranulosis and basal vacuolar alteration, and superficial perivascular lymphohistiocytic infiltrate with melanophages (Figure 2). Direct immunofluorescence studies and fungal cultures were negative. The cutaneous features of a treatment-resistant acral dermatosis supported the clinical diagnosis of AP, especially in the setting of an internal malignancy. The patient was started on palliative radiotherapy with no notable resolution of the cutaneous lesions. She was lost to follow-up.

Figure 1. Palmoplantar keratoderma with central sparing of the palms and soles, onycholysis, and subungual hyperkeratosis .

First described by Bazex et al¹ in 1965, AP is an uncommon but well-recognized paraneoplastic dermatosis associated with an underlying neoplasm. Fewer than 160 cases have been reported, and the majority of cases have been men older than 40 years. The most commonly associated malignancy was SCC (at least 50% of reported cases) involving mainly the oropharynx and larynx, with lung and esophageal SCC also described.^2-4 Only a few cases of adenocarcinoma-associated AP have been described, such as adenocarcinoma of the lung, prostate, and stomach.^3-5 In a reported case of AP associated with early colon adenocarcinoma, the patient had remarkable cutaneous resolution following successful tumor resection.⁶ Other reported rare hematologic associations included Hodgkin disease, peripheral T-cell lymphoma, and multiple myeloma.^3-5 Karabulut et al⁴ described a case associated with cholangiocarcinoma and studied the primary sites of malignancies in another 133 patients with AP (118 patients with documented cell type): oropharynx and larynx in 55 (41%); lung in 23 (17%); unknown location in 20 (15%); esophagus in 14 (11%); prostate in 3 (2%); stomach in 3 (2%); and isolated cases involving the liver, thymus, uterus, vulva, breast, urinary bladder, lymph nodes, and bone marrow.

Figure 2. Histologic examination revealed basal vacuolar alteration, hyperkeratosis, and superficial perivascular lymphohistiocytic infiltrate with melanophages (H&amp;E, original magnification ×40).

A review of 113 cases of AP showed that only 15% developed cutaneous lesions after the malignancy had been discovered; in the majority of cases (67%), cutaneous lesions were present for an average of 1 year preceding the diagnosis of malignancy.³ In our patient, the late-onset cutaneous involvement corresponded to the progression of the underlying colon adenocarcinoma. In the absence of initial cutaneous involvement or when successful treatment of a tumor results in cutaneous resolution, subsequent emergence of cutaneous lesions of AP signifies tumor progression. The evolution of cutaneous features in AP was well described by Bazex et al.¹ Stage 1 of the disease shows initial erythema and psoriasiform scaling of the fingers and toes, spreading to the nose and ear helices (hence acrokeratosis); the tumor frequently remains asymptomatic or undetected. Stage 2 shows palmoplantar keratoderma with central sparing and more extensive facial lesions; progression to stage 3 occurs if the tumor remains undetected or untreated, with further spread of psoriasiform lesions to the elbows, knees, trunk, and scalp.¹ Nail involvement occurs in nearly 75% of cases⁵; typical changes include subungual hyperkeratosis, onycholysis, longitudinal streaks, yellow pigmentation, and rarely onychomadesis. A high index of suspicion of AP is paramount when evaluating any recalcitrant acral dermatosis that fails to respond to appropriate therapy, especially in the presence of constitutional symptoms, typical bulbous enlargement of distal phalanges, or isolated involvement of helices. These findings should prompt physicians to perform an extensive search for an underlying malignancy with complete physical examination, particularly of the head and neck region, with appropriate endoscopic assessment and imaging studies.

A myriad of nonspecific histologic features of AP commonly reported include hyperkeratosis, parakeratosis, acanthosis, and dermal perivascular lymphohistiocytic infiltrate.⁷ Less common features include dyskeratotic keratinocytes, vacuolar degeneration, bandlike infiltrate, and melanin incontinence.⁷ The pathogenesis of AP remains elusive. A postulated immunologic mechanism is based on reports of immunoglobulins (IgG, IgA, IgM) and complement (C3) deposition along the basement membrane zone.⁸ Association with autoimmune disorders such as alopecia areata and vitiligo also has been reported.⁹ Another possible mechanism is cross-reactivity between antigens found in the tumor and skin, resulting in a T-cell–mediated immune response to tumorlike antigens in the epidermis, or secretion of tumor-originating growth factors responsible for the hyperkeratotic skin changes, such as epidermal growth factor, transforming growth factor a, or insulinlike growth factor 1.^3,7,10,11

Spontaneous remission of cutaneous lesions in untreated underlying malignancy is rare. Isolated reports of treatment using topical and systemic steroids, salicylic acid, topical vitamin D analogues, etretinate, and psoralen plus UVA showed minimal improvement.^5,7 The mainstay in attaining cutaneous resolution is to detect and eradicate the underlying neoplasm with surgery, chemotherapy, or radiotherapy, or combination therapy.

Our case is noteworthy because of the patient’s gender (female), underlying malignancy (adenocarcinoma of the colon), and late onset of cutaneous involvement, which are all uncommon associations related to paraneoplastic syndrome. The clinical features of AP should be recognized early to facilitate an extensive search for an occult malignancy, and late-onset cutaneous involvement also should be recognized as a marker of tumor relapse or progression.

To the Editor:

Acrokeratosis paraneoplastica (AP) of Bazex is a rare but distinctive acral psoriasiform dermatosis associated with internal malignancy, usually squamous cell carcinoma (SCC), of the upper aerodigestive tract.^1,2 Recognizing this paraneoplastic condition is paramount because cutaneous findings often precede the onset of symptoms associated with an occult malignancy.³

A 76-year-old woman with adenocarcinoma of the transverse colon of 3 years’ duration was referred to the dermatology department. She had a hemicolectomy and was doing well until tumor recurrence with peritoneal metastasis was detected following an exploratory laparotomy 1 year prior to presentation to us. She underwent a total hysterectomy and bilateral salpingo-oophorectomy. Palliative chemotherapy was initiated, and she completed 5 cycles of capecitabine and oxaliplatin. Long-term medications for diabetes mellitus, hypertension, and hyperlipidemia included glibenclamide, nifedipine, hydrochlorothiazide, and losartan. The patient had a progressive pruritic rash of 6 months’ duration that started on the hands and forearms and spread to involve the feet and lower limbs as well as the ears and face. She also experienced progressive thickening of the palms and soles. She had been treated with topical steroids and emollients with no improvement. Clinical examination revealed erythematous scaly patches on all of her limbs, especially on the elbows and knees, and on the ear helices and nose. There also was notable palmoplantar keratoderma with central sparing (Figure 1), onycholysis, and subungual hyperkeratosis. A skin biopsy of the forearm was performed, and histology revealed orthokeratosis, hypergranulosis and basal vacuolar alteration, and superficial perivascular lymphohistiocytic infiltrate with melanophages (Figure 2). Direct immunofluorescence studies and fungal cultures were negative. The cutaneous features of a treatment-resistant acral dermatosis supported the clinical diagnosis of AP, especially in the setting of an internal malignancy. The patient was started on palliative radiotherapy with no notable resolution of the cutaneous lesions. She was lost to follow-up.

Figure 1. Palmoplantar keratoderma with central sparing of the palms and soles, onycholysis, and subungual hyperkeratosis .

First described by Bazex et al¹ in 1965, AP is an uncommon but well-recognized paraneoplastic dermatosis associated with an underlying neoplasm. Fewer than 160 cases have been reported, and the majority of cases have been men older than 40 years. The most commonly associated malignancy was SCC (at least 50% of reported cases) involving mainly the oropharynx and larynx, with lung and esophageal SCC also described.^2-4 Only a few cases of adenocarcinoma-associated AP have been described, such as adenocarcinoma of the lung, prostate, and stomach.^3-5 In a reported case of AP associated with early colon adenocarcinoma, the patient had remarkable cutaneous resolution following successful tumor resection.⁶ Other reported rare hematologic associations included Hodgkin disease, peripheral T-cell lymphoma, and multiple myeloma.^3-5 Karabulut et al⁴ described a case associated with cholangiocarcinoma and studied the primary sites of malignancies in another 133 patients with AP (118 patients with documented cell type): oropharynx and larynx in 55 (41%); lung in 23 (17%); unknown location in 20 (15%); esophagus in 14 (11%); prostate in 3 (2%); stomach in 3 (2%); and isolated cases involving the liver, thymus, uterus, vulva, breast, urinary bladder, lymph nodes, and bone marrow.

Figure 2. Histologic examination revealed basal vacuolar alteration, hyperkeratosis, and superficial perivascular lymphohistiocytic infiltrate with melanophages (H&amp;E, original magnification ×40).

A review of 113 cases of AP showed that only 15% developed cutaneous lesions after the malignancy had been discovered; in the majority of cases (67%), cutaneous lesions were present for an average of 1 year preceding the diagnosis of malignancy.³ In our patient, the late-onset cutaneous involvement corresponded to the progression of the underlying colon adenocarcinoma. In the absence of initial cutaneous involvement or when successful treatment of a tumor results in cutaneous resolution, subsequent emergence of cutaneous lesions of AP signifies tumor progression. The evolution of cutaneous features in AP was well described by Bazex et al.¹ Stage 1 of the disease shows initial erythema and psoriasiform scaling of the fingers and toes, spreading to the nose and ear helices (hence acrokeratosis); the tumor frequently remains asymptomatic or undetected. Stage 2 shows palmoplantar keratoderma with central sparing and more extensive facial lesions; progression to stage 3 occurs if the tumor remains undetected or untreated, with further spread of psoriasiform lesions to the elbows, knees, trunk, and scalp.¹ Nail involvement occurs in nearly 75% of cases⁵; typical changes include subungual hyperkeratosis, onycholysis, longitudinal streaks, yellow pigmentation, and rarely onychomadesis. A high index of suspicion of AP is paramount when evaluating any recalcitrant acral dermatosis that fails to respond to appropriate therapy, especially in the presence of constitutional symptoms, typical bulbous enlargement of distal phalanges, or isolated involvement of helices. These findings should prompt physicians to perform an extensive search for an underlying malignancy with complete physical examination, particularly of the head and neck region, with appropriate endoscopic assessment and imaging studies.

A myriad of nonspecific histologic features of AP commonly reported include hyperkeratosis, parakeratosis, acanthosis, and dermal perivascular lymphohistiocytic infiltrate.⁷ Less common features include dyskeratotic keratinocytes, vacuolar degeneration, bandlike infiltrate, and melanin incontinence.⁷ The pathogenesis of AP remains elusive. A postulated immunologic mechanism is based on reports of immunoglobulins (IgG, IgA, IgM) and complement (C3) deposition along the basement membrane zone.⁸ Association with autoimmune disorders such as alopecia areata and vitiligo also has been reported.⁹ Another possible mechanism is cross-reactivity between antigens found in the tumor and skin, resulting in a T-cell–mediated immune response to tumorlike antigens in the epidermis, or secretion of tumor-originating growth factors responsible for the hyperkeratotic skin changes, such as epidermal growth factor, transforming growth factor a, or insulinlike growth factor 1.^3,7,10,11

Spontaneous remission of cutaneous lesions in untreated underlying malignancy is rare. Isolated reports of treatment using topical and systemic steroids, salicylic acid, topical vitamin D analogues, etretinate, and psoralen plus UVA showed minimal improvement.^5,7 The mainstay in attaining cutaneous resolution is to detect and eradicate the underlying neoplasm with surgery, chemotherapy, or radiotherapy, or combination therapy.

Our case is noteworthy because of the patient’s gender (female), underlying malignancy (adenocarcinoma of the colon), and late onset of cutaneous involvement, which are all uncommon associations related to paraneoplastic syndrome. The clinical features of AP should be recognized early to facilitate an extensive search for an occult malignancy, and late-onset cutaneous involvement also should be recognized as a marker of tumor relapse or progression.